ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Source: Globenewswire
Biogen's ZURZUVAE Approval: Biogen announced that the European Medicines Agency's CHMP has recommended marketing authorization for ZURZUVAE (zuranolone) to treat postpartum depression in adults, potentially making it the first EU-approved treatment specifically for this condition.
Clinical Study Results: The recommendation is based on positive results from the SKYLARK Study, which showed significant reductions in depressive symptoms as early as Day 3 of a 14-day treatment course, with ZURZUVAE being generally well-tolerated by patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
